- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abbisko Cayman Ltd (2256)
Abbisko Cayman Ltd stock price live, this page displays HK 2256 stock exchange data. View the 2256 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abbisko Cayman Ltd real time stock price chart below.
What Is the Abbisko Cayman Ltd Stock Price Today?
The Abbisko Cayman Ltd stock price today is 10.51.
What Is the Stock Symbol for Abbisko Cayman Ltd?
The stock symbol for Abbisko Cayman Ltd is "2256."
What Stock Exchange Does Abbisko Cayman Ltd Trade On?
Abbisko Cayman Ltd is listed and trades on the Hong Kong stock exchange.
Is Abbisko Cayman Ltd a Good Stock to Buy?
Determining whether Abbisko Cayman Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2256 quote. (ISIN: KYG0028A1085)
What Is the Abbisko Cayman Ltd Stock Price Today?
The Abbisko Cayman Ltd stock price today is 10.51.
What Is the Stock Symbol for Abbisko Cayman Ltd?
The stock symbol for Abbisko Cayman Ltd is "2256."
What Stock Exchange Does Abbisko Cayman Ltd Trade On?
Abbisko Cayman Ltd is listed and trades on the Hong Kong stock exchange.
Is Abbisko Cayman Ltd a Good Stock to Buy?
Determining whether Abbisko Cayman Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2256 quote. (ISIN: KYG0028A1085)
Hong Kong
Currency in HKD
10.51
-0.22(-2.05%)
Closed·
Fair Value
An estimate of a Abbisko Cayman's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.36
10.76
52 wk Range
8.34
19.78
2256 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Abbisko Cayman's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.3610.76
52 wk Range
8.3419.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2256 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Abbisko Cayman's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
21.64
Upside
+105.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.64
(+105.92% Upside)
Earnings
Latest Release
Mar 02, 2026
EPS / Forecast
-0.44 / --
Revenue / Forecast
-- / --
Compare 2256 to Peers and Sector
Metrics to compare | 2256 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2256PeersSector | |
|---|---|---|---|---|
P/E Ratio | 120.2x | −4.5x | −0.4x | |
PEG Ratio | 0.96 | 0.02 | 0.00 | |
Price/Book | 3.5x | 4.6x | 2.6x | |
Price / LTM Sales | 10.8x | 7.6x | 2.9x | |
Upside (Analyst Target) | 102.1% | 58.4% | 58.0% | |
Fair Value Upside | Unlock | 16.4% | 9.5% | Unlock |
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. Further, it is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Additionally, the company provides advisory and management services. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Abbisko Cayman (2256) Stock Price Today?
The Abbisko Cayman stock price today is 10.51 HKD.
What Stock Exchange Does Abbisko Cayman Trade On?
Abbisko Cayman is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Abbisko Cayman?
The stock symbol for Abbisko Cayman is "2256."
What Is the Abbisko Cayman Market Cap?
As of today, Abbisko Cayman market cap is 7.53B HKD.
What Is Abbisko Cayman's Earnings Per Share (TTM)?
The Abbisko Cayman EPS (TTM) is 0.09.
From a Technical Analysis Perspective, Is 2256 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Abbisko Cayman Stock Split?
Abbisko Cayman has split 0 times.
How Many Employees Does Abbisko Cayman Have?
Abbisko Cayman has 276 employees.
What is the current trading status of Abbisko Cayman (2256)?
As of Jul 27, 2026, Abbisko Cayman (2256) is trading at a price of 10.51 HKD, with a previous close of 10.51 HKD. The stock has fluctuated within a day range of 10.36 HKD to 10.76 HKD, while its 52-week range spans from 8.34 HKD to 19.78 HKD.
What Is Abbisko Cayman (2256) Price Target According to Analysts?
The average 12-month price target for Abbisko Cayman is 21.64 HKD, with a high estimate of 25.15119917 HKD and a low estimate of 17.56459275 HKD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +105.92% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.